北京中关村科技发展（控股）股份有限公司关于下属公司山东华素琥珀酸美托洛尔原料药获批上市的公告

Core Viewpoint - The announcement highlights that Shandong Huasu Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) for the marketing of Succinic Acid Metoprolol raw materials, which is expected to enhance the company's market competitiveness and operational performance [1][3]. Group 1: Approval Details - The chemical raw material approved is Succinic Acid Metoprolol, with the application number CYHS2460273 and notification number 2025YS00723 [1]. - The approval indicates that the product meets the relevant requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1]. Group 2: Product Background - Succinic Acid Metoprolol is a selective β1-adrenergic receptor blocker, initially developed in 1969, used clinically for treating hypertension, angina, and heart failure [2]. - There are currently 16 manufacturers listed for Succinic Acid Metoprolol raw materials, with 12 classified as "A" status and 4 as "I" status according to the CDE raw and auxiliary material registration information platform [2]. Group 3: Impact on the Company - The approval of Succinic Acid Metoprolol provides a stable raw material source for the company's ongoing research into sustained-release capsules, thereby enhancing the competitiveness of related products [3]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug development, manufacturing, and sales processes [3].